JP2020536116A - ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法 - Google Patents

ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法 Download PDF

Info

Publication number
JP2020536116A
JP2020536116A JP2020520037A JP2020520037A JP2020536116A JP 2020536116 A JP2020536116 A JP 2020536116A JP 2020520037 A JP2020520037 A JP 2020520037A JP 2020520037 A JP2020520037 A JP 2020520037A JP 2020536116 A JP2020536116 A JP 2020536116A
Authority
JP
Japan
Prior art keywords
benzo
carboxamide
thiazol
fluoro
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536116A5 (enExample
Inventor
イ，ジンファ
チョ，スヨン
パク，アヨン
イ，グウィビン
キム，ジェウン
キム，ミスン
チョン，ギュスン
イム，スンムク
イム，キョンスン
イ，ミヌ
ヤン，ヘギョン
キム，ヒョナム
キム，ヒョンジュン
リ，ワンジュン
ファン，ミンジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1St Biotherapeutics Inc
Original Assignee
1St Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1St Biotherapeutics Inc filed Critical 1St Biotherapeutics Inc
Publication of JP2020536116A publication Critical patent/JP2020536116A/ja
Publication of JP2020536116A5 publication Critical patent/JP2020536116A5/ja
Priority to JP2023080175A priority Critical patent/JP7605898B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2020520037A 2017-10-02 2018-10-01 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法 Pending JP2020536116A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023080175A JP7605898B2 (ja) 2017-10-02 2023-05-15 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762566649P 2017-10-02 2017-10-02
US62/566,649 2017-10-02
US201862666800P 2018-05-04 2018-05-04
US62/666,800 2018-05-04
US201862696432P 2018-07-11 2018-07-11
US62/696,432 2018-07-11
PCT/KR2018/011660 WO2019070093A1 (en) 2017-10-02 2018-10-01 BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080175A Division JP7605898B2 (ja) 2017-10-02 2023-05-15 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2020536116A true JP2020536116A (ja) 2020-12-10
JP2020536116A5 JP2020536116A5 (enExample) 2021-11-11

Family

ID=65897719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520037A Pending JP2020536116A (ja) 2017-10-02 2018-10-01 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法
JP2023080175A Active JP7605898B2 (ja) 2017-10-02 2023-05-15 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023080175A Active JP7605898B2 (ja) 2017-10-02 2023-05-15 ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法

Country Status (15)

Country Link
US (2) US10669246B2 (enExample)
EP (1) EP3692023B1 (enExample)
JP (2) JP2020536116A (enExample)
KR (1) KR102858188B1 (enExample)
CN (1) CN111315727B (enExample)
AU (1) AU2018346051B2 (enExample)
CA (1) CA3078173A1 (enExample)
ES (1) ES2953025T3 (enExample)
FI (1) FI3692023T3 (enExample)
HU (1) HUE062526T2 (enExample)
IL (1) IL273705B2 (enExample)
MX (1) MX2020003593A (enExample)
PL (1) PL3692023T3 (enExample)
PT (1) PT3692023T (enExample)
WO (1) WO2019070093A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062526T2 (hu) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzotiazol vegyületek és azokat alkalmazó eljárások neurodegeneratív rendellenességek kezelésére
US11098044B2 (en) 2019-02-22 2021-08-24 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
JP7456641B2 (ja) * 2019-03-07 2024-03-27 ファースト・バイオセラピューティクス・インコーポレイテッド Ｐｅｔ放射性トレーサーとしての［１８ｆ］標識ベンゾチアゾール誘導体
US10385046B1 (en) * 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
JP7604387B2 (ja) * 2019-03-28 2024-12-23 ファースト・バイオセラピューティクス・インコーポレイテッド ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
CN110483402B (zh) * 2019-08-12 2021-07-23 上海毕得医药科技股份有限公司 一种3-溴-5-苯基-1h-吡唑的合成方法
EP4200269A1 (en) * 2020-08-21 2023-06-28 1st Biotherapeutics, Inc. [ 18F]-LABELED IMIDAZOPYRIDINE DERIVATIVES AS PET RADIOTRACER

WO2022038574A1 (en) * 2020-08-21 2022-02-24 1ST Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
US11834467B2 (en) * 2020-09-28 2023-12-05 1ST Biotherapeutics, Inc. Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors
KR20230084145A (ko) * 2020-09-30 2023-06-12 아사히 가세이 파마 가부시키가이샤 피리미딘 함유 함질소 2환 화합물
TWI898106B (zh) * 2022-01-11 2025-09-21 日商旭化成製藥股份有限公司 含有嘧啶之含氮雙環化合物
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522800A (ja) * 1997-11-10 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー ベンゾチアゾールたんぱくチロシン・キナーゼ抑制剤
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010144909A1 (en) * 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
JP2011527692A (ja) * 2008-07-08 2011-11-04 インテリカイン， インコーポレイテッド キナーゼインヒビターおよび使用方法
JP2014502601A (ja) * 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1187453A (en) * 1915-09-20 1916-06-13 Allis Chalmers Mfg Co Steam-turbine.
US2258671A (en) * 1940-01-27 1941-10-14 Nat Oil Prod Co Refining of fat-soluble vitamincontaining materials
CN1422262A (zh) 2000-02-07 2003-06-04 艾博特股份有限两合公司 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
EP2183232B1 (en) 2007-08-02 2013-03-06 Amgen, Inc Pi3 kinase modulators and methods of use
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
JP4528849B2 (ja) * 2008-07-14 2010-08-25 シャープ株式会社 引出し型加熱調理器
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
KR20140107153A (ko) * 2014-07-23 2014-09-04 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
HUE062526T2 (hu) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzotiazol vegyületek és azokat alkalmazó eljárások neurodegeneratív rendellenességek kezelésére

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522800A (ja) * 1997-11-10 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー ベンゾチアゾールたんぱくチロシン・キナーゼ抑制剤
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP2011527692A (ja) * 2008-07-08 2011-11-04 インテリカイン， インコーポレイテッド キナーゼインヒビターおよび使用方法
WO2010144909A1 (en) * 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
JP2014502601A (ja) * 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HWANGSEO PARK ET AL.: "Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure", J. AM. CHEM. SOC., vol. 135, no. 22, JPN7022004648, 2013, pages 8227 - 8237, ISSN: 0004888160 *
SEUNGHEE HONG ET AL.: "Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Includin", J. MED. CHEM., vol. 56, no. 9, JPN7022004647, 2013, pages 3531 - 3545, ISSN: 0004888161 *
矢ヶ崎史治: "ＩＶ．最近のトピックス ２．チロシンキナーゼ阻害薬", 日本内科学会雑誌, vol. 第９６巻、第７号, JPN7022004649, 2007, pages 1411 - 1419, ISSN: 0004888162 *

Also Published As

Publication number Publication date
CN111315727A (zh) 2020-06-19
EP3692023A4 (en) 2021-04-07
IL273705B (en) 2022-10-01
KR102858188B1 (ko) 2025-09-11
AU2018346051B2 (en) 2022-11-10
HUE062526T2 (hu) 2023-11-28
RU2020112784A (ru) 2021-11-09
US20190100500A1 (en) 2019-04-04
US20200270222A1 (en) 2020-08-27
AU2018346051A1 (en) 2020-04-09
KR20200051832A (ko) 2020-05-13
US10669246B2 (en) 2020-06-02
ES2953025T3 (es) 2023-11-07
US10968188B2 (en) 2021-04-06
EP3692023A1 (en) 2020-08-12
MX2020003593A (es) 2020-07-22
CN111315727B (zh) 2023-09-29
WO2019070093A1 (en) 2019-04-11
PT3692023T (pt) 2023-08-23
JP7605898B2 (ja) 2024-12-24
CA3078173A1 (en) 2019-04-11
JP2023109868A (ja) 2023-08-08
RU2020112784A3 (enExample) 2022-03-05
IL273705B2 (en) 2023-02-01
FI3692023T3 (fi) 2023-08-17
IL273705A (en) 2020-05-31
PL3692023T3 (pl) 2023-12-11
EP3692023B1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
JP7605898B2 (ja) ベンゾオチアゾール化合物及び神経変性障害を治療するためにそれを使用する方法
US12086788B2 (en) Substituted pyrazines as inhibitors of BTK, and mutants thereof
JP6947651B2 (ja) ４，６−ピリミジニレン誘導体およびこれらの使用
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
KR101750125B1 (ko) 티아졸 및 옥사졸 키나제 저해제
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
JP2022020611A (ja) サイクリン依存性キナーゼの阻害剤
RS64221B1 (sr) Modulatori piruvat kinaze i njihova upotreba
KR20160127826A (ko) 비장 티로신 키나제 억제제로서 치환된 옥사졸 유도체
RU2778370C2 (ru) Бензотиазольные соединения и способы их применения для лечения нейродегенеративных расстройств
HK40022715B (zh) 苯并噻唑化合物及使用其治疗神经退行性疾病的方法
KR20210026359A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
WO2019235501A1 (ja) ヒストン脱アセチル化酵素阻害剤
WO2023072966A1 (en) Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
JP2024528729A (ja) Ｓｒｐｋインヒビター
KR20210032357A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210929

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117